Skip to main content
Terug
Watch Compare

Sonoma Pharmaceuticals, Inc.

Datakwaliteit: 100%
SNOA
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 2,41
▲ € 0,12 (5,24%)
Marktkapitalisatie: 4,17 M
Prijs
€ 2,41
Marktkapitalisatie
4,17 M
Dagbereik
€ 2,23 — € 2,60
52-Weeksbereik
€ 1,92 — € 6,92
Volume
82.136
Openen € 2,30
50D / 200D Gem.
€ 2,73
11,73% below
50D / 200D Gem.
€ 3,48
30,81% below

Quick Summary

Belangrijkste Punten

Revenue declined -6,42% annually over 5 years
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -3,72 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 18,61%
Capital efficient — spends only 1,18% of revenue on capex

Groei

Revenue Growth (5Y)
-6,42%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)12,19%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-93,36%
Onder sectorgemiddelde (-53,41%)
ROIC-23,01%
Net Margin-19,02%
Op. Margin-15,61%

Veiligheid

Debt / Equity
0,00
Onder sectorgemiddelde (0,31)
Current Ratio2,88
Interest CoverageN/A

Waardering

PE (TTM)
-1,24
Boven sectorgemiddelde (-1,48)
P/B Ratio1,22
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,2 -1,5
P/B 1,2 1,6
ROE % -93,4 -53,4
Net Margin % -19,0 -41,5
Rev Growth 5Y % -6,4 1,8
D/E 0,0 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 12,19% Revenue Growth (3Y) 3,76%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -6,42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 17,72 M Net Income (TTM) -3,37 M
ROE -93,36% ROA -24,53%
Gross Margin 38,16% Operating Margin -15,61%
Net Margin -19,02% Free Cash Flow (TTM) -3,72 M
ROIC -23,01% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 2,88
Interest Coverage N/A Asset Turnover 1,29
Working Capital 7,93 M Tangible Book Value 3,43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,24 Forward P/E N/A
P/B Ratio 1,22 P/S Ratio 0,24
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -89,17%
Market Cap 4,17 M Enterprise Value 1,61 M
Per Share
EPS (Diluted TTM) -1,95 Revenue / Share 10,24
FCF / Share -2,15 OCF / Share -2,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,18% FCF Conversion 110,36%
SBC-Adj. FCF -3,85 M Growth Momentum 18,61

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,29 M 12,74 M 13,27 M 12,63 M 18,63 M
Net Income -3,46 M -4,84 M -5,15 M -5,09 M -3,95 M
EPS (Diluted) -2,79 -0,53 -1,52 — —
Gross Profit 5,47 M 4,75 M 4,48 M 3,99 M 6,56 M
Operating Income -3,71 M -4,70 M -4,57 M -5,89 M -3,45 M
EBITDA — — — — —
R&D Expenses 1,81 M 1,87 M 207.000,0 125.000,0 555.000,0
SG&A Expenses 7,36 M 7,58 M 8,84 M 9,76 M 9,45 M
D&A 138.000,0 176.000,0 125.000,0 186.000,0 227.000,0
Interest Expense — — 16.000,0 -10.000,0 12.000,0
Income Tax 550.000,0 -196.000,0 -33.000,0 -332.000,0 713.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13,69 M 14,74 M 16,23 M 18,85 M 14,99 M
Total Liabilities 9,28 M 8,60 M 8,25 M 10,15 M 9,62 M
Shareholders' Equity 4,41 M 6,14 M 7,98 M 8,70 M 5,36 M
Total Debt 220.000,0 323.000,0 — 0,0 1,31 M
Cash & Equivalents 5,37 M 3,13 M 3,82 M 7,40 M 4,22 M
Current Assets 12,65 M 12,55 M 13,80 M 16,43 M 12,98 M
Current Liabilities 4,10 M 3,72 M 3,72 M 5,82 M 4,08 M